4503.T · available-data snapshot
Astellas Pharma Inc. (4503.T): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Astellas Pharma Inc. (4503.T); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for 4503.T?
We do not publish a fair value for Astellas Pharma Inc.. What we can say from its filings and market data is below.
What is 4503.T's TickerWorth Score?
Scores higher than almost every company we compare it with
Compared with Healthcare companies in Japan
Its strongest point: looks cheap on the numbers.
- Value · 87 of 100
Cheaper than 87% of Healthcare companies worldwide
- Price vs worth · 100 of 100
- Quality · 81 of 100
More profitable than 81% of Healthcare companies worldwide
- Financial health · 52 of 100
Financially stronger than 52% of Healthcare companies worldwide
- Growth · 57 of 100
Growing faster than 57% of Healthcare companies worldwide
- Momentum · 84 of 100
Outperformed 84% of Healthcare companies worldwide over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- ¥2,
425 - Market cap
- ¥4,
348, 058, 271, 744 - 52-week high
- ¥2,
717 - 52-week low
- ¥1,
558 - Currency
- JPY
- Exchange
- Tokyo
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Astellas Pharma Inc. (4503.T) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, 4503.T trades at a recent price of ¥2,425, a market capitalisation of about ¥4,348,058,271,744, sitting 75% of the way up its 52-week range (¥1,558–¥2,717), on the Tokyo.
The standard alternative to a DCF is relative valuation — comparing 4503.T's trading multiples against a sector benchmark. Here that gives P/E of 11.9× (cheaper than the peer median of 41.9×); Fwd P/E of 32.0× (richer than the peer median of 17.5×); P/B of 2.2× (cheaper than the peer median of 7.8×); P/S of 1.9× (cheaper than the peer median of 6.2×); EV/EBITDA of 7.0× (cheaper than the peer median of 18.5×); Dividend yield of 3.3% (cheaper than the peer median of 2.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. 4503.T shows a price-to-book (P/B) of 2.24 and book value of ¥1,083 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. 4503.T is in an up-trend (price above both its 50- and 200-day averages), trading -10.7% from its 52-week high. Over the past year the stock is +48.7%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
4503.T vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | 4503.T | Peer median | Read |
|---|---|---|---|
| P/E | 11.9× | 41.9× | cheaper than |
| Fwd P/E | 32.0× | 17.5× | richer than |
| P/B | 2.2× | 7.8× | cheaper than |
| P/S | 1.9× | 6.2× | cheaper than |
| EV/EBITDA | 7.0× | 18.5× | cheaper than |
| Dividend yield | 3.3% | 2.4% | cheaper than |
What does Astellas Pharma Inc. do?
What does it do?
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in Japan. The company employs roughly 14,099 people.
How does it make money?
The business turns 2.3T in annual revenue into profit. Out of every $100 of sales, about $29 is left as operating profit (operating margin of 28.9%), after a 81% gross margin on the products/services it sells. After all costs, taxes and interest, 16.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries modest debt (0.3× equity), can just cover its short-term bills (1.2× current ratio), and is currently profitable.
4503.T insider trading
Insider filings are available for US-listed companies only.
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.